Sabcs 2018 Abstracts Online
Puma Biotechnology Presents Interim Results Of Phase Ii Control Trial Of Neratinib In Extended Adjuvant Treatment Of Her2 Positive Early Stage Breast Cancer At The 2019 Sabcs Business Wire
Puma Biotechnology Presents Interim Results Of Phase Ii Control Trial Of Neratinib In Extended Adjuvant Treatment Of Her2 Positive Early Stage Breast Cancer At The 2019 Sabcs Business Wire